The severe hypertriglyceridemia market is expected to experience steady growth, driven by the rising prevalence of obesity, diabetes, metabolic syndrome, and other cardiometabolic disorders associated with elevated triglyceride levels. Additionally, the expected launch of emerging therapies such as Plozasiran (ARO-APOC3; Arrowhead Pharmaceuticals), Pegozafermin (BIO89-100; 89bio), Solbinsiran (LY3561774; Eli Lilly and Company), ION775 (Ionis Pharmaceuticals), and others will further propel the market growth.

LAS VEGAS, Oct. 20, 2026 /PRNewswire/ -- Recently published Severe Hypertriglyceridemia Market Insights report includes a comprehensive understanding of current treatment practices, severe hypertriglyceridemia emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Severe Hypertriglyceridemia Market Summary

- The total severe hypertriglyceridemia treatment market size is expected to grow positively by 2036 in the leading markets.

- The United States accounted for the largest severe hypertriglyceridemia treatment market size in the 7MM in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

- The total number of diagnosed prevalent cases of SHTG in the 7MM were nearly 3.64 million cases in 2025 and is projected to increase during the forecast period.

- Leading severe hypertriglyceridemia companies, such as Arrowhead Pharmaceuticals, 89bio, Eli Lilly and Company, Ionis Pharmaceuticals, CRISPR Therapeutics, Northsea Therapeutics B.V., and others, are developing new severe hypertriglyceridemia treatment drugs that can be available in the severe hypertriglyceridemia market in the coming years.

- The promising severe hypertriglyceridemia therapies in clinical trials include Plozasiran (ARO-APOC3), Pegozafermin (BIO89-100), Solbinsiran (LY3561774), ION775, CTX310, SEFA-1024 (NST-1024), and others.

Discover the new therapeutic targets for severe hypertriglyceridemia @ https://www.delveinsight.com/report-store/severe-hypertriglyceridemia-shtg-market

Key Factors Driving the Growth of the Severe Hypertriglyceridemia Market

- Rising Prevalence of Metabolic Disorders: The increasing burden of obesity, type 2 diabetes, metabolic syndrome, and other cardiometabolic conditions is contributing to higher triglyceride levels. The growing prevalence of these risk factors is expected to expand the severe hypertriglyceridemia patient pool.

- Advances in RNA-Based Therapeutics: Progress in antisense oligonucleotide and other RNA-targeted technologies is enabling the development of therapies designed to directly regulate pathways involved in triglyceride metabolism. These innovations are broadening the treatment landscape for patients with severe hypertriglyceridemia.

- Emergence of Ionis' TRYNGOLZA: Ionis' TRYNGOLZA (olezarsen) approval is expected to strengthen the treatment landscape for severe hypertriglyceridemia (sHTG), providing a targeted therapeutic option for patients with markedly elevated triglyceride levels. Its approval may increase competition in a market historically characterized by limited disease-specific treatment options and reliance on triglyceride-lowering agents.

- Launch of Emerging SHTG Drugs: The dynamics of the SHTG market are expected to change in the coming years due to the launch of emerging therapies such as Plozasiran (ARO-APOC3; Arrowhead Pharmaceuticals), Pegozafermin (BIO89-100; 89bio), Solbinsiran (LY3561774; Eli Lilly and Company), ION775 (Ionis Pharmaceuticals), CTX310 (CRISPR Therapeutics), SEFA-1024 (NST-1024; Northsea Therapeutics B.V.), and others.

Aparna Thakur, Project Manager of Forecasting & Analytics at DelveInsight, said that for Ionis, TRYNGOLZA approval is more than a new product launch; it's the company's first fully independent commercial rollout in a prevalent disease, a meaningful step up from its historical focus on rare conditions. With plozasiran's sHTG trials maturing and several other mechanisms in the wings, TRYNGOLZA's window of uncontested leadership may be measured in a few short years rather than a decade.

Severe Hypertriglyceridemia Market Analysis

- Treatment for severe hypertriglyceridemia typically includes dietary and lifestyle modifications alongside lipid-lowering therapies such as fibrates, omega-3 fatty acids, statins, and niacin. Among these therapies, statins currently account for the largest share of the market, followed by fibrates.

- Despite the availability of established treatments, including statins, fibrates, and omega-3 fatty acids, SHTG continues to substantially affect patients' quality of life, highlighting a significant unmet need for more effective therapeutic options.

- VASCEPA (icosapent ethyl) is FDA-approved for the treatment of SHTG and cardiovascular risk reduction. However, its triglyceride-lowering effect is relatively modest, and treatment is associated with risks such as atrial fibrillation and bleeding.

- In June 2026, the FDA approved Ionis' TRYNGOLZA as the first and only treatment indicated to reduce triglyceride levels and the risk of acute pancreatitis in patients with severe hypertriglyceridemia. The approval for sHTG was supported by data from the Phase 3 CORE and CORE2 trials.

- The therapeutic landscape is also evolving with the development of novel treatment approaches across multiple molecular classes, including antisense oligonucleotides, small interfering RNA (siRNA), recombinant proteins, and small-molecule therapies.

- Leading companies such as Arrowhead Pharmaceuticals, with plozasiran; 89bio, with pegozafermin; and NorthSea Therapeutics, with SEFA-1024, among others, are actively evaluating their respective drug candidates.

Severe Hypertriglyceridemia Competitive Landscape

Some of the severe hypertriglyceridemia drugs under development include Plozasiran (ARO-APOC3; Arrowhead Pharmaceuticals), Pegozafermin (BIO89-100; 89bio), Solbinsiran (LY3561774; Eli Lilly and Company), ION775 (Ionis Pharmaceuticals), CTX310 (CRISPR Therapeutics), SEFA-1024 (NST-1024; Northsea Therapeutics B.V.), and others.

Arrowhead Pharmaceuticals' Plozasiran (formerly ARO-APOC3) is an investigational RNA interference (RNAi) therapy designed to reduce the production of apolipoprotein C-III (ApoC3) through the endogenous RNAi pathway. ApoC3 is produced primarily by liver cells and plays a role in regulating lipid and lipoprotein metabolism, including the production and clearance of triglyceride-rich particles.

89bio's Pegozafermin is an investigational fibroblast growth factor 21 (FGF21) analog developed using glycoPEGylation technology and site-specific mutations to replicate key biological activities of native FGF21 while extending its half-life. By targeting underlying metabolic dysfunction, pegozafermin has the potential to address liver and cardiometabolic diseases, including metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG).

Ionis' ION775 is an investigational apolipoprotein C-III (apoC-III) small interfering RNA (siRNA) therapy being evaluated in patients with severe hypertriglyceridemia (sHTG). The therapy is designed to provide durable apoC-III suppression, with the potential to support a twice-yearly dosing regimen. ION775 represents Ionis' first siRNA medicine to enter clinical development.

Northsea Therapeutics' SEFA-1024 is an oral, gut- and liver-targeted, semi-synthetic eicosapentaenoic acid (EPA) derivative under development for the treatment of severe hypertriglyceridemia (sHTG). The condition is associated with a substantially elevated risk of acute pancreatitis and may also contribute to increased cardiovascular event risk. Significant unmet need remains due to the limited efficacy of currently available therapies in reducing triglycerides (TG) and non-HDL cholesterol while improving glycemic control. Supported by extensive preclinical data from a translatable human hypertriglyceridemia model, SEFA-1024 may have the potential to address some of the limitations associated with current sHTG treatment approaches.

The anticipated launch of these emerging therapies are poised to transform the severe hypertriglyceridemia market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the severe hypertriglyceridemia market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Discover more about the severe hypertriglyceridemia treatment market @ Severe Hypertriglyceridemia Drugs

Recent Developments in the Severe Hypertriglyceridemia Market

- In August 2026, Arrowhead Pharmaceuticals, Inc. presented findings from the pivotal Phase 3 SHASTA-3 and SHASTA-4 trials evaluating plozasiran in adults with severe hypertriglyceridemia (sHTG) at the Hot Line Late-Breaking Science session during the 2026 European Society of Cardiology (ESC) Congress in Munich, Germany.

- In August 2026, Ionis Pharmaceuticals, Inc. presented the new data on the management of severe hypertriglyceridemia (sHTG) at the 2026 European Society of Cardiology (ESC) Congress, scheduled to take place from August 28–31 in Munich.

- In August 2026, Arrowhead Pharmaceuticals, Inc. announced that it has entered into an agreement with an undisclosed third party to acquire a U.S. Food and Drug Administration (FDA) Rare Pediatric Disease Priority Review Voucher (PRV). Arrowhead plans to use the PRV in connection with its anticipated Supplemental New Drug Application (sNDA) for plozasiran, which is expected to be submitted by the end of 2026. The application will seek to expand plozasiran's approved indication to include patients with severe hypertriglyceridemia (sHTG).

- In June 2026, Ionis Pharmaceuticals announced that the U.S.

Simple changes and added support can help older adults remain safer and more independent at home

SCOTTSDALE, Ariz., Oct. 20, 2026 /PRNewswire/ -- As shorter days and changing weather keep older adults indoors more often, Executive Home Care, a leading in-home care service provider, encourages families to make their loved ones' homes safer before winter.

Falls are the leading cause of injury among adults 65 and older, and more than one in four reports falling each year, according to the Centers for Disease Control and Prevention. Many risks can be reduced by identifying hazards and changes in mobility, strength or daily routines.

"A fall can change an older adult's independence in an instant, but families can reduce many everyday risks with a careful walk-through and the right support," said Jeanette Weinz, president of Executive Home Care. "The best time to make a home safer is before a close call."

Five Areas Families Should Check Before Winter

Executive Home Care recommends that families:

- Clear walking paths and stairs. Remove loose rugs, cords and clutter. Ensure stairs are well-lit and have handrails.

- Improve lighting. Check hallways, bedrooms, bathrooms and entrances during shorter winter days.

- Improve bathroom safety. Consider grab bars, nonslip surfaces and other supports.

- Review health and mobility changes. Consult a health care professional about falls, balance or strength changes, vision concerns, dizziness or medications that may affect stability.

- Prepare for winter disruptions. Plan for meals, transportation, medication access and personal care if severe weather makes travel difficult.

- Bruising, difficulty standing, an unsteady gait, missed meals, changes in personal care or reluctance to use stairs may indicate that an older loved one needs support.

"Families don't have to wait for an emergency before asking whether an older loved one needs additional help," Weinz said. "Changes in strength, mobility or daily routines can be early signs that it's time to have that conversation."

In-home caregivers can assist with care, meal preparation, light housekeeping, mobility and companionship, helping older adults maintain their routines and independence.

Learn more at www.executivehomecare.com.

About Executive Home Care

Executive Home Care, a member of Evive Brands, provides in-home care that helps older adults and individuals with care needs remain safe, comfortable and independent. Services include companionship, personal care, homemaking, live-in care and specialized Alzheimer's and dementia care.

Contact: [email protected]

SOURCE Executive Home Care

Share this article

Celebrating four decades of precision dosing, PrecisePK connects directly to Epic, Cerner, and Sentri7 so patient data comes to clinicians and more time goes to patient care.

SAN DIEGO, Oct. 20, 2026 /PRNewswire/ -- PrecisePK, a therapeutic drug monitoring (TDM) software company used by hospital systems worldwide, is highlighting its electronic health record (EHR) and clinical surveillance integrations this year, building on more than 40 years of precision dosing experience since launching from UC San Diego in 1985.

That foundation supports PrecisePK's continued efforts in direct EHR integration, which connects its dosing platform to the systems pharmacists already use every shift. Its integrations with Epic and Cerner (Oracle Health) automatically import vancomycin doses and administration times from the eMAR, along with serum creatinine results, patient demographics, vancomycin levels and specimen collection times; information pharmacists previously had to enter by hand.

That same principle extends to Sentri7®, Wolters Kluwer's clinical surveillance platform, which PrecisePK integrated with through a 2022 partnership. Pharmacists can launch PrecisePK directly from a patient's case within Sentri7, with demographics, dosing history and lab values carrying over automatically.

These integrations allow clinicians to move from the EHR to dosing recommendations without redundant logins or re-typed data, so the time saved on data entry goes back into patient care.

"Manual data entry isn't just a time cost for pharmacists, it's a point where errors can creep into patient care," said Anjum Gupta, CEO of PrecisePK. "More than 40 years ago, this company was built to make dosing decisions more precise. That same standard now applies to the data feeding those decisions, where every value that flows in through Epic, Cerner or Sentri7 is handled with the same rigor our clinical team applies to validating each drug model."

That rigor extends across the rest of the platform as well:

- Extensive Drug Coverage: Support for over 20 classes, including vancomycin, aminoglycosides, and select oncology and cardiology medications.

- Rigorous Validation: Each drug model is clinically validated by an internal team of clinical experts and partnered hospitals to ensure precision and reliability before market release.

- Seamless Implementation: A structured 4-to-7 week timeline covers pre-setup, configuration, and final clinical validation.

- Data Integrity: Strict adherence to HIPAA standards and data principles to ensure enterprise-grade security.

With over 40 years of experience in precision dosing, PrecisePK supports healthcare teams in 20+ countries in making safer, better-informed medication decisions. Looking ahead, PrecisePK remains committed to advancing precision dosing and helping clinicians deliver better patient care.

About PrecisePK

PrecisePK is a therapeutic drug monitoring software platform that provides personalized, model-informed dosing recommendations for vancomycin and other medications. Originally founded in 1985 as T.D.M.S. 2000, PrecisePK is backed by over 40 years of clinical use and has grown into a globally used precision dosing platform trusted by academic medical centers, community hospitals, and government health systems. PrecisePK is based in San Diego, California. For more information, visit www.precisepk.com.

SOURCE PrecisePK

Share this article

New capabilities within Vee, Visier's Workforce Insights Agent, explains the "why" and "how" behind complex workforce metrics, giving every business leader defensible analysis that once required a dedicated data scientist

VANCOUVER, BC and LAS VEGAS, October 20, 2026 /PRNewswire/ -- Visier announced the early access launch of diagnostics capabilities within the Visier Workforce Insights Agent, Vee. Most organizations can see that resignations spiked or time-to-fill slowed but proving why, with enough data science rigor to be credible, has traditionally meant weeks of manual analysis, a dedicated data scientist, or both. Visier uses statistical models to explain complex workforce changes, helping leaders interpret what is working and what isn't, then offering recommendations on what to do about it.

Vee, Visier's Workforce Insights Agent, runs on the Workforce Intelligence Platform, a workforce context engine built from 16+ years of workforce domain expertise that maps, governs, and secures workforce data for people, systems, and AI agents alike. Millions of users already have secure access to governed workforce insights thanks to Vee and Visier's MCP, launched in late 2025, extends those same governed insights to any AI agent or enterprise tool.

With the Diagnostics capabilities, users are now able to:

- Explain the "why" and "how", not just "who," "what," and "where," highlighting the difference between descriptive analytics and a real explanation

- Run rigorous statistical models (the Vee Diagnostics feature will contain multiple statistical options ensuring the right business problem is aligned with the best model to solve it) to find the actual drivers behind a change

- Show the math by ranking every factor it evaluated, flagging confidence levels, while keeping a full audit trail so any answer it delivers is defensible

- Model the projected impact of changing a specific driver, so leaders act on the right lever instead of guessing

- Built into Vee at no additional cost, which means no new tool, workflow, or headcount required to gain the benefits of this capability

For two decades, talent management got solved the same way: another tool bolted onto systems that were never connected to outcomes. Enterprises are now racing to put AI on top of those same disconnected systems, and fragmented data doesn't get smarter with AI, it gets faster at guessing. Boards and CFOs are asking HR to prove that talent investments move the business, and most vendors can't reliably answer that without weeks of manual analysis.

"Vee tells you why your workforce changed and what to do about it which, for a lot of teams, is the difference between having a data point and having an actual decision," said Ian Cook, VP Product, Visier adding "It's like having a Data Scientist on your shoulder, ready to deliver accurate and credible insights."

"The way to get business leaders to agree on talent decisions is for the foundation of the discussion to be rooted in credible and trustworthy data and insights supported by statistical rigor," said Zachary Chertok, Research Director for HCM Applications and Agents at IDC, "Visier's Workforce Insights Agent, Vee, provides the workforce intelligence business leaders are seeking in an approachable way and for a wide range of workforce data users directly inside the workflows they are already using."

This capability delivers what HR leaders need, a data science analyst at the ready: this is not simply a nice to have, it's mandatory for top performing HR teams. Innovations, like Vee, help CHROs and their teams more deeply understand their workforce to provide more value and more impact to their organizations.

These capabilities are available now as part of our early access program for select Visier customers. General availability and additional statistical models are on the roadmap for Winter 2027.

You can see Vee diagnostics in action at the Visier booth #5209 at HR Tech 2026, Mandalay Bay, Oct 20–22, UNLEASH World (booth #106), and Total Talent Asia (booth #3). Learn more about Visier's Workforce Insights Agent Vee here.

About Visier

Visier Workforce AI is the context foundation for talent management. The Visier Workforce Intelligence Platform turns scattered, sensitive people data into one governed understanding of the entire workforce, so organizations can understand, plan, and activate all of their talent priorities in one place. More than 85,000 of the world's most complex organizations, including Ford Motor Company, eBay, Experian, and Domino's Pizza, rely on Visier's over 16 years of workforce domain expertise, ranked #1 in vendor satisfaction and user experience for three consecutive years by the Sapient Insights HR Systems Survey. Learn more at Visier.com.

SOURCE Visier

Share this article

CHICAGO, Oct. 20, 2026 /PRNewswire/ -- To help physicians, medical specialists, researchers, board certification professionals, and the public learn more about board certification, the American Board of Medical Specialties (ABMS) has released the 2025-2026 ABMS Board Certification Report. ABMS also updated the ABMS Data Viewer, which provides free access to aggregated board certification data collected by ABMS and its 24 Member Boards, enabling users to explore and better understand the distribution of board certified physicians and specialists across the U.S. healthcare system.

According to the latest report, more than one million physicians and medical specialists (diplomates) are certified by an ABMS Member Board. ABMS board certification provides an independent evaluation of a physician or medical specialist's knowledge and skills, serving as a trusted credential patients can rely upon when selecting a provider for their healthcare needs.

"ABMS board certification indicates to patients that their physician or medical specialist has met rigorous standards for knowledge and skills," said Richard E. Hawkins, MD, ABMS President and Chief Executive Officer. "By pairing the latest certification report with the enhanced Data Viewer, ABMS is making trusted information more accessible and helping patients better understand the evolving physician workforce."

The 2025-2026 ABMS Board Certification Report reflects a growing population of diplomates who use board certification to demonstrate their specialty expertise and continued commitment to provide safe, high-quality, and effective care.

The new report offers updated, interesting facts about the ABMS board certification landscape and diplomates, including (as of June 30, 2026):

- 1,020,705 diplomates hold an active certification.

- 36,206 new specialty certificates and 15,018 new subspecialty certificates were awarded.

- 796,162 diplomates were participating in continuing certification.

- The breakdown of age and gender for the diplomate population continues to change over time. Currently, 35.3% of all active diplomates are women, while 58.3% are men. Note that 6.3 % of diplomates are unknown.

- Younger diplomates (35-44 years old) are nearly evenly distributed between males (46.7%) and females (43.5%), with approximately 9.8% of diplomates' genders unknown.

Introduced in 2025, the ABMS Data Viewer makes aggregated data available with filtered views. It is organized by Member Board Overview, U.S. Certificates, Continuing Certification Participation, U.S. State Distribution, and International Certificates. Within each view, users may apply filters such as age, gender, specialty, and geographic location. The updated ABMS Data Viewer includes the ability to choose a specific month of interest. It currently includes June, July, and August 2026, with months being added throughout the year.

ABMS also recently published the 2027 ABMS Guide to Medical Specialties. This edition of the guide provides an overview of board certification and descriptions of each specialty and subspecialty area in which physicians may be certified.

About ABMS

Established in 1933, the American Board of Medical Specialties (ABMS) is responsible for the creation of standards overseeing physician certification in the United States. Dedicated to improving the quality of care to the patients, families, and communities they serve, the 24 ABMS Member Boards develop educational and professional standards and programs of assessment to certify physicians and medical specialists. More than one million physicians and medical specialists are certified by one or more of the ABMS Member Boards in one or more of 38 specialties and 90 subspecialties. For more information about ABMS, visit abms.org or call (312) 436-2600.

SOURCE American Board of Medical Specialties

Share this article

TOKYO, Oct. 20, 2026 /PRNewswire/ -- bitBiome, Inc. (Headquarters: Tokyo; Representative Director and CEO: Yuji Suzuki) is pleased to announce the achievement of target milestones stipulated in the joint development contract with Ajinomoto Co., Inc. (Headquarters: Chuo-ku, Tokyo; President & CEO: Shigeo Nakamura), which was previously announced on December 21, 2023. In recognition of this milestone, bitBiome has received the associated success fee.

In this project, bitBiome utilized its proprietary microbial database, "bit-GEM," and its biomanufacturing development platform, "bit-EVO", to discover novel enzymes. Following detailed analysis by Ajinomoto Co., Inc., it was confirmed that the newly discovered enzymes met target requirements set forth by Ajinomoto Co., Inc.

Comment from the Project Lead at Ajinomoto Co., Inc.:

"Leveraging bitBiome's extensive microbial database and advanced discovery platform, we were able to identify promising enzyme candidates at a pace that exceeded our expectations. This achievement highlights the value of open innovation, and we look forward to further accelerating research and development through continued collaboration while creating new value together."

Comment from Yuji Suzuki, Representative Director and CEO of bitBiome, Inc.: 

"This project powerfully demonstrates the potential of microbial genomic assets and the strategic advantage of our 'treasure island' database. Our success in identifying enzymes directly from this resource showcases the unparalleled diversity of our microbial collection, providing a unique dataset that is unavailable in the public realm."

The enzymes discovered through this project will undergo further evaluation by Ajinomoto Co., Inc. as they consider future social implementation. bitBiome remains committed to contributing to the realization of sustainable biomanufacturing by providing innovative bio-solutions based on microbial data.

About bitBiome:

bitBiome is a biotechnology company unlocking the full potential of our planet's microbes to power the future of the bioeconomy. bitBiome's platform is built on their proprietary single-cell microbial genome analysis technology, bit-MAP ®, which has enabled the creation of bit-GEM: an extensive and groundbreakingly diverse and growing microbial database of over 4 billion sequences, sourced primarily from environmental samples and predominantly containing sequences not present in public databases. Leveraging their expertise in bioinformatics, machine learning and unique use of AI technologies, the company practices a comprehensive enzyme discovery and enzyme, pathway and diversified strain engineering platform, bit-EVO, to rapidly develop and manufacture bio-based products. bitBiome is committed to improving existing biomanufacturing industries and creating new ones by delivering unique nature-inspired bio-based products that cannot be enabled elsewhere.

To learn more about bitBiome's platform and services, visit www.bitbiome.bio.

Contact: [email protected]

Additional links:

https://bitbiome.bio/news/bitbiome-and-ajinomoto-co-inc-sign-joint-research-agreement-on-novelenzyme-discovery/

SOURCE bitBiome

Share this article

Award recognizes the Company's local watershed funds, started in Michigan and since expanded to California and Texas, which support conserving, enhancing, and restoring watersheds in local communities

TAMPA, Fla. and STAMFORD, Conn., Oct. 20, 2026 /PRNewswire/ -- Primo Brands Corporation (NYSE: PRMB) ("Primo Brands" or the "Company"), a leading North American branded beverage company focused on healthy hydration, today announced that it has received the International Bottled Water Association's (IBWA) 2026 Environmental Stewardship Award. The award, presented during IBWA's annual conference at Mohegan Sun in Uncasville, Conn., recognizes member companies for creating and carrying out sustainable environmental projects and conservation measures.

"Every one of our regional spring water brands comes from specific spring sources, and the health of the sources matters not just today, but to the local community for generations to come," said Charles Fogg, Chief Sustainability Officer of Primo Brands, who accepted the award alongside Senior Natural Resource Manager Greg Fox. "This recognition belongs to the teams of hydrogeologists, biologists, and experts who work on the ground with our local partners to help protect the natural resources and our communities every day. We're grateful to IBWA for recognizing it."

Primo Brands received the award for its Ice Mountain® Environmental Stewardship Fund, which for 23 years has partnered with local organizations in Michigan's Muskegon River Watershed on projects that benefit area residents and natural resources. Its most recent round of grants, $78,100 across six local organizations and administered by the Fremont Area Community Foundation, includes the Muskegon River Watershed Assembly's work to add buffer zones and expand tree canopy along the Clam River, and TrueNorth Community Services' restoration of wetland habitat and the Camp Newaygo Wetland Trail after a 2024 brushfire.

In March 2026, Primo Brands extended that successful model to two more of its regional spring water brands, launching Environmental Stewardship Funds for Arrowhead® Mountain Spring Water in Southern California's Santa Ana River watershed and Ozarka® Texas Spring Water in the San Jacinto Watershed in the Houston region. Each new fund launched with $250,000 in initial funding as part of a four-year, $1 million commitment, and is administered by a local partner, the Inland Empire Community Foundation and the Greater Houston Community Foundation, respectively. Together, the two watersheds span more than 8,000 square miles and serve more than 12 million residents, with grants supporting work that ranges from habitat restoration and wildfire fuel reduction to groundwater resilience and flood risk management.

"A spring is only as healthy as the land and water around it," said Greg Fox, Senior Natural Resource Manager at Primo Brands. "The Ice Mountain fund showed how we can deliver real impact when local groups lead and we back them. Watching that same approach take hold in California and Texas this year has been incredibly inspiring."

The funds are one piece of Primo Brands' comprehensive approach to water stewardship across more than 80 springs, including the conservation of more than 28,000 acres of recharge land. In 2025, the Company replenished 400 million gallons of water locally, and it has set a goal of 100% water replenishment in high water-stress areas by 2035. Additional details are available in the Company's 2025 Sustainability Report.

The award follows IBWA's 2022 Environmental Stewardship Award to Primo Water Corporation, one of the two companies that combined to form Primo Brands.

About Primo Brands Corporation

Primo Brands is a leading North American branded beverage company focused on healthy hydration, delivering responsibly sourced diversified offerings across products, formats, channels, price points, and consumer occasions, distributed in every U.S. state and Canada.

Primo Brands has a comprehensive portfolio of highly recognizable and conveniently packaged branded water and beverages that reach consumers whenever, wherever, and however they hydrate through distribution across retail outlets, away from home such as hotels and hospitals, and food service accounts, as well as direct delivery to homes and businesses. These brands include established "billion-dollar brands" Poland Spring® and Pure Life®, premium brands like Saratoga® and The Mountain Valley®, regional leaders such as Arrowhead®, Deer Park®, Ice Mountain®, Ozarka®, and Zephyrhills®, purified water brands including Primo Water® and Sparkletts®, and flavored and enhanced brands like Splash Refresher® and AC+ION®. Primo Brands also has an industry-leading line-up of innovative water dispensers, which create consumer connectivity through recurring water purchases.

Primo Brands operates a vertically integrated coast-to-coast network that distributes its brands to more than 200,000 retail outlets, as well as directly reaching consumers through its Direct Delivery, Exchange and Refill offerings. Through Direct Delivery, Primo Brands delivers responsibly sourced hydration solutions direct to home and business customers. Through its Exchange business, consumers can visit approximately 26,500 retail locations and purchase a pre-filled, multi-serve bottle of water that can be exchanged after use for a discount on the next purchase. Through its Refill business, consumers have the option to refill empty multi-use bottles at approximately 23,500 self-service refill stations. Primo Brands also offers water filtration units for home and business customers across North America. For more information, please visit www.primobrands.com.

SOURCE DS Services of America, Inc. dba Primo Water North America

Share this article

COLUMBUS, Ohio, Oct. 20, 2026 /PRNewswire/ -- The Board of Directors of American Electric Power (Nasdaq: AEP) has declared a regular quarterly cash dividend of 97 cents per share on the company's common stock, an increase of 2 cents per share.

The dividend is payable Dec. 10, 2026, to shareholders of record as of Nov. 10, 2026.

About AEP

American Electric Power (Nasdaq: AEP) is committed to improving our customers' lives with reliable, affordable power. We plan to invest $78 billion from 2026 through 2030 to enhance service for customers and support the growing energy needs of our communities. Our nearly 18,000 employees operate and maintain the nation's largest electric transmission system with 40,000 line miles, along with more than 252,000 miles of distribution lines to deliver energy to 5.6 million customers in 11 states. AEP also is one of the nation's largest electricity producers with approximately 33,000 megawatts of diverse owned and contracted generating capacity. We are focused on safety and operational excellence, creating value for our stakeholders and bringing opportunity to our service territory through economic development and community engagement. Our family of companies includes AEP Texas, Appalachian Power (in Virginia, West Virginia and Tennessee), Indiana Michigan Power, Kentucky Power, Ohio Power Company, Public Service Company of Oklahoma, and Southwestern Electric Power Company (in Arkansas, Louisiana, east Texas and the Texas Panhandle). AEP also owns AEP Energy, which provides innovative competitive energy solutions nationwide. AEP is headquartered in Columbus, Ohio. For more information, visit aep.com.

Website Disclosure

AEP may use its website as a distribution channel for material company information. Financial and other important information regarding AEP is routinely posted on and accessible through AEP's website at https://www.aep.com/investors/. In addition, you may automatically receive email alerts and other information about AEP when you enroll your email address by visiting the "Email Alerts" section at https://www.aep.com/investors/.

SOURCE American Electric Power

Share this article

The new partnership expands LAZ's charging network to 25,000 ports across North America and lays the groundwork for a broader relationship focused on sustainable local transportation.

HARTFORD, Conn. and BOSTON, Oct. 20, 2026 /PRNewswire/ -- LAZ Parking ("LAZ") and EverCharge, a wholly-owned subsidiary of indiGOtech (tradename: GO), today announced a joint venture to accelerate the deployment of sustainable EV charging for residents of apartments and condos, with LAZ Multifamily EV Charging Powered by EverCharge SmartPower™ as its first offering. The venture combines LAZ's extensive parking and real-estate footprint with EverCharge's SmartPower management technology while establishing a foundation for a broader strategic relationship between LAZ and GO around the future of sustainable local transportation. EverCharge's proven SmartPower™ technology lets chargers share a building's available power, allowing up to 5X more ports to be used with the same source power, so more residents can charge without a major electrical upgrade.

The partnership brings together significant physical infrastructure and proven EV charging technology. LAZ operates approximately 2.1 million parking spaces across 5,700 locations in 639 cities, providing a substantial presence in the United States and Canada. EverCharge brings more than a decade of EV charging experience, with patented charging technologies, and operates more than 10,000 installed charging ports across 1,000-plus multi-unit residential sites serving more than 50,000 registered drivers.

Multifamily EV Charging, now available across LAZ's nationwide footprint, will initially focus on solving the fundamental problem for residents in apartments and condos, also known as multi-unit dwellings (MUD). Unlike single-family homeowners who can often install dedicated chargers, residents of multi-unit properties rely on shared electrical and parking infrastructure, where electrical capacity, installation complexity, and utility upgrade costs can make large-scale charging difficult.

EverCharge's patented SmartPower™ dynamic load-management technology addresses this challenge by intelligently allocating available electrical capacity across multiple charging vehicles, enabling up to 5X more ports to be used with the same source power. This lets property owners expand charging capacity within existing grid constraints, reduce expensive infrastructure upgrades, while satisfying many more tenants. EverCharge's EVO3 Level 2 chargers are best-in-class for reliability, with an industry-leading 55 Degree Celsius temperature rating that no other competitor has to date. Combined with LAZ's parking-management capabilities and relationships with property owners and operators, Multifamily EV Charging is designed to provide a scalable, turnkey solution for residents' EV charging and to help more people make the switch to electric.

Multifamily is the starting point. The strategic relationship also creates opportunities beyond the initial MUD market. GO is developing an integrated sustainable local transportation ecosystem built around three interconnected layers: energy, vehicles, and intelligent orchestration. GO's EverCharge provides the intelligent energy infrastructure, GO's patented SmartWheels™ enable roomier, smoother electric and autonomous vehicles, and GO Loop operates intelligent transport with vehicles and charging infrastructure to bridge drivers, riders and transportation demand for communities.

"LAZ has always been about more than parking. We connect people with the places they're going, and the future is charging right where people park," said Alan Lazowski, Chairman and CEO of LAZ. "Our joint venture with GO expands our charging network to 25,000 ports across North America, and we're just getting started. Our broader relationship with GO also gives the opportunity to explore how the places we operate can grow alongside electric and autonomous vehicles."

"Multi-unit dwelling (MUD) charging represents one of the largest infrastructure opportunities in the transition to electric transportation," said John Lin, CEO of EverCharge. "We're the leader in deploying intelligent charging for this market, and we're excited to work with LAZ to bring our platform to substantially more properties and drivers."

"We're rethinking the infrastructure that powers local transportation," said Will Graylin, Chairman of GO. "Our vision for this relationship with LAZ is to show how real estate, energy, vehicles and intelligent orchestration can converge to create a more sustainable and efficient transport ecosystem for urban communities."

As transportation becomes increasingly electric, connected, and software-managed, GO and LAZ will start with MUD customers' needs and explore the right charging and battery-swap infrastructure for commercial fleets, ride-hail, and delivery services.

About LAZ

LAZ is the largest privately owned, technology-enabled parking and transportation company in North America, connecting people, partners and communities to what's possible. Founded in Hartford, Connecticut, in 1981, LAZ manages the places where people, vehicles and goods converge across commercial, residential, institutional and municipal properties. More than 23,000 team members operate approximately 2.1 million parking spaces at 5,700 locations in 44 states, eight provinces and 639 cities across the United States and Canada, supported by pioneering digital technology that helps every space work harder for the owners who trust LAZ.

About indiGOtech (GO)

indiGOtech (GO for short), builds and operates a unified mobility ecosystem for sustainable local transportation connecting energy, vehicles and intelligent orchestration. The GO ecosystem includes patented SmartPower™ charging infrastructure, patented SmartWheels™ vehicle technology, purpose-built electric and autonomous vehicles and GO Loop mobility and fleet-management solutions. GO's vision is to unify every aspect of electric and autonomous urban mobility, to significantly improve the economics, efficiency and sustainability of local ride-hail, delivery and urban transportation.

About EverCharge

EverCharge is a nationwide provider of intelligent EV charging hardware, software and energy-management solutions and a leader in multi-unit dwelling and fleet charging infrastructure. Founded in 2013, EverCharge's patented SmartPower™ technology dynamically manages available electrical capacity, enabling multi-family and commercial properties to deploy greater EV charging capacity within existing electrical constraints. EverCharge operates more than 1,000 MUD sites with 10,000+ installed charging ports serving more than 50,000 registered drivers. EverCharge is a wholly owned subsidiary of indiGOtech (GO).

SOURCE LAZ Parking

Share this article

CATL Unveils Dual-Electric Range Extension Battery to Accelerate Electric Heavy-Duty Truck Adoption

BEIJING, Oct. 20, 2026 /PRNewswire/ -- CATL today unveiled the innovative dual-electric range extension battery and the latest generation of heavy-duty battery-swapping solution to accelerate the electrification of road freight transportation.

Competition in electric heavy-duty trucking is moving beyond technical specifications toward full-lifecycle value. While battery swapping has made energy replenishment faster and more predictable, concerns about battery utilization, operating costs and residual vehicle value continue to affect fleet economics.

To address these challenges, CATL combines its dual-electric range extension battery with QIJI's strategy of standardization, new infrastructure and a full commercial ecosystem, bringing battery swapping and industry-wide collaboration together to accelerate heavy-duty truck electrification.

A Dual-Electric Approach to Range Extension

CATL's dual-electric range extension battery combines two independent yet complementary battery systems.

The main battery uses QIJI's standardized chassis-mounted swappable battery to maximize efficiency. A behind-the-cab range-extension power system, currently equipped with a 77kWh battery capable of 3C charging, provides backup power. Together, the systems maintain uninterrupted power delivery and provide redundancy for demanding operating conditions.

- Dual-System Power Redundancy

In conventional battery-swapping trucks, drivers often return for a swap with unused capacity because they are reluctant to run the battery low. Backup power from the range-extension battery increases the main battery's depth of discharge (DOD) from approximately 70% to over 95%, allowing it to be returned at less than 5% state of charge (SOC). At this threshold, CATL's seamless switching technology transfers power delivery to the range-extension battery within milliseconds, maintaining a continuous and stable power supply.

- "1+X" Architecture and Independent Upgrades

The system uses a "1+X" architecture. One standardized main battery maintains compatibility with the QIJI battery-swapping network, while the range-extension battery can be customized for specific conditions with options including ultra-high energy density, low-temperature resistance for cold climates, or ultra-high power.

The two battery systems can be developed and upgraded independently to meet their respective technical and operational requirements.

- Flexible Leasing and Battery Asset Management

The independently owned on-board range-extension battery stays with the vehicle as an asset throughout its service life, reducing reliance on immediate access to a swapping station. The main battery can be leased according to seasonal freight demand, helping fleets reduce rental costs during quieter periods and manage battery assets more flexibly.

This architecture combines the benefits of standardization with flexible vehicle configurations, making electric heavy-duty trucks more practical and economically viable across a wider range of applications.

QIJI Builds a Shared Battery Swapping Ecosystem

QIJI complements these improvements with a three-pillar strategy of standardization, new infrastructure and a full commercial ecosystem. It seeks to speed heavy-duty truck electrification with a value-chain ecosystem co-created by all stakeholders, where benefits are shared collectively.

- Standardization Supports Wider Adoption

To accommodate a wider range of truck models and operating conditions, QIJI has introduced the 260# (432 kWh) and 300# (513 kWh) standardized battery-swapping blocks alongside the existing 75# block.

The system enables battery swaps in just five minutes, with a 99.99% first-time success rate, helping fleets minimize downtime and maintain operational efficiency.

QIJI has also pioneered a battery-as-a-service (BaaS) model in which customers pay for the net energy charged rather than the energy discharged. This allows customers to retain the value of energy recovered through regenerative braking, reducing per-kWh battery rental costs for users on basic plans by up to 20%. Flexible battery leasing options allow customers to tailor rental periods to their needs, from second-hand vehicle transitions to seasonal demand. This will minimize idle costs and offer more flexible options for off-season downtime, further helping fleets manage operating costs.

- New Infrastructure Improves Resource Efficiency

QIJI aims to make better use of four critical resources in long-haul freight: time, land, payload capacity and grid electricity. Rapid battery swapping reduces waiting times, while efficient station layouts serve more vehicles within the same footprint. Battery capacity is matched to transport needs, and centralized, coordinated charging makes better use of grid electricity. These measures aim to improve both resource efficiency and operational returns.

CATL plans to deploy 900 battery-swapping stations by the end of 2026 and 2,000 by 2027, with a long-term target of 10,000 stations nationwide in collaboration with its partners.

By connecting major freight corridors through a coordinated swapping network, QIJI aims to improve the efficiency and commercial viability of electric heavy-duty trucking.

- A Commercial Ecosystem Supports the Full Vehicle Lifecycle

QIJI connects truck manufacturers, financial institutions, insurers, channel partners and aftermarket service providers across the vehicle lifecycle, from purchase and operation to maintenance and resale, working together to build a comprehensive ecosystem of integrated products and services.

QIJI has introduced two partnership models: Battery Asset Service Partners and Energy Replenishment Service Partners. These models allow partners to participate in battery asset services and energy replenishment, extending their role beyond one-off vehicle sales to ongoing operations.

Through this integrated ecosystem, QIJI aims to turn the costs of the low-carbon transition into new growth opportunities, enabling stakeholders across the value chain to share the benefits of the new-energy era.

"The combination of the dual-electric range extension battery and QIJI battery swapping offers the best solution for electrifying heavy-duty trucks," said Jesse Yang, CEO of QIJI Energy.

New Batteries and Industry Partnerships

The initiative has also gained commercial traction, with agreements signed for 13,000 units at the event.

Aside from the dual-electric solution, CATL also introduced a new lineup of heavy-duty truck batteries tailored to different vehicle configurations and operating requirements at the event. The lineup includes rear-mounted ultra-light and ultra-thin batteries for weight- and space-sensitive applications, as well as chassis-mounted solutions for short-haul and long-haul operations.

SOURCE CATL

Share this article